| __timestamp | MiMedx Group, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 1860000 |
| Thursday, January 1, 2015 | 133384000 | 2963000 |
| Friday, January 1, 2016 | 179997000 | 6961000 |
| Sunday, January 1, 2017 | 220119000 | 11779000 |
| Monday, January 1, 2018 | 258528000 | 13697000 |
| Tuesday, January 1, 2019 | 198205000 | 15749000 |
| Wednesday, January 1, 2020 | 181022000 | 18638000 |
| Friday, January 1, 2021 | 198359000 | 27196000 |
| Saturday, January 1, 2022 | 208789000 | 31739000 |
| Sunday, January 1, 2023 | 211124000 | 33491000 |
Data in motion
In the competitive landscape of biotechnology and medical devices, understanding financial health is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, MiMedx Group consistently outspent Protagonist Therapeutics, with SG&A expenses peaking in 2018 at approximately 258 million dollars, a 185% increase from 2014. In contrast, Protagonist Therapeutics saw a more modest rise, with expenses growing nearly 18 times from 2014 to 2023, reaching around 33 million dollars. This stark difference highlights MiMedx's aggressive spending strategy compared to Protagonist's more conservative approach. Such insights are invaluable for investors and stakeholders aiming to gauge the operational strategies and financial priorities of these companies. As the industry evolves, tracking these expenses can offer a window into future growth and sustainability strategies.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.
PTC Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: MorphoSys AG vs Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.